Home Newsfeeds Wedbush Maintains Outperform on M/I Homes, Raises Price Target to $73

Wedbush Maintains Outperform on M/I Homes, Raises Price Target to $73

Wedbush analyst Jay McCanless maintains M/I Homes (NYSE:MHO) with a Outperform and raises the price target from $63 to $73.

byBenzinga Newsdesk

February 6, 2023

1 minute read

Wedbush analyst Jay McCanless maintains M/I Homes (NYSE:MHO) with a Outperform and raises the price target from $63 to $73.

Analyst Ratings

Beyond The Numbers: 6 Analysts Discuss Dynatrace Stock

By Benzinga Insights

January 5, 12:01 PM

Dynatrace (NYSE:DT) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish…

Rosenblatt Maintains Neutral on Meta Platforms, Lowers Price Target to $181

By Benzinga Newsdesk

July 25, 7:37 AM

Rosenblatt analyst Barton Crockett maintains Meta Platforms (NASDAQ:META) with a Neutral and lowers the price target from $212 to $181.

DaVita Q2 EPS $2.30 Beats $2.09 Estimate, Sales $2.93B Miss $2.93B Estimate

By Benzinga Newsdesk

August 1, 4:35 PM

DaVita (NASDAQ:DVA) reported quarterly earnings of $2.30 per share which beat the analyst consensus estimate of $2.09 by 10.05 percent. This is a 12.88 percent decrease over earnings of $2.64 per share from the same

DVA

BioLineRx Announces Publication In Nature Medicine Of Its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide And G-CSF In Stem Cell Mobilization For Autologous Transplantation In Multiple Myeloma

By Happy Mohamed

April 17, 11:01 AM

- GENESIS trial achieved statistical significance (p<0.0001) across all primary and secondary endpoints - - Nature Medicine publication describes how GENESIS trial included patients representative of current

BLRX

Wedbush Maintains Outperform on M/I Homes, Raises Price Target to $73

Related Posts

Beyond The Numbers: 6 Analysts Discuss Dynatrace Stock

Rosenblatt Maintains Neutral on Meta Platforms, Lowers Price Target to $181

DaVita Q2 EPS $2.30 Beats $2.09 Estimate, Sales $2.93B Miss $2.93B Estimate

BioLineRx Announces Publication In Nature Medicine Of Its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide And G-CSF In Stem Cell Mobilization For Autologous Transplantation In Multiple Myeloma